Novo Nordisk AS (NVO)
88.00
+0.63
(+0.72%)
USD |
NYSE |
Dec 26, 15:00
Novo Nordisk Free Cash Flow: 9.828B for Sept. 30, 2024
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Ascendis Pharma AS | -- |
| Evaxion Biotech AS | -- |
| Amgen Inc | 6.283B |
| Viking Therapeutics Inc | -74.25M |
| Akari Therapeutics PLC | -14.84M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 6.658B |
| Cash from Investing (Quarterly) | -3.131B |
| Cash from Financing (Quarterly) | -2.741B |
| Free Cash Flow Per Share (Quarterly) | 1.064 |
| Free Cash Flow to Equity (Quarterly) | 4.406B |
| Free Cash Flow to Firm (Quarterly) | 4.748B |
| Free Cash Flow Yield | 2.50% |